{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:20:32Z","timestamp":1774891232569,"version":"3.50.1"},"reference-count":86,"publisher":"Becaris Publishing Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>More interventions that better manage cardiovascular disease are urgently needed in the Middle East. To discuss this issue, we held a symposium at the Heart Masters Middle East 2023 congress (Dubai, UAE; May 2023) on personalized management of angina and heart failure (HF). This narrative review summarizes the content of our symposium. Many patients with chronic stable angina have ongoing symptoms and poor quality of life (QoL) despite beta-blocker\u00a0+\u00a0calcium-channel blocker therapy and revascularization. Further, angina is often under-recognized in clinical practice. Clinicians should consider adding newer antianginal agents (long-acting nitrates, ranolazine, trimetazidine, ivabradine) to beta-blockers\u00a0+\u00a0calcium-channel blockers based on patient risk factors. Individualized therapy is recommended because several mechanisms can cause angina. Agents that act at a cellular level (e.g., trimetazidine) can prevent ischemia in cardiomyocytes. Trimetazidine provides early and sustained antianginal effects, with improvements in myocardial metabolism and exercise capacity. In our view, trimetazidine may be considered as second-line therapy for angina that is suboptimally controlled on first-line therapy, and could be added to first-line therapy for angina occurring after myocardial infarction or revascularization, and comorbid with diabetes. Ivabradine reduces elevated heart rate and, when added to beta-blockers, improves angina symptoms, exercise capacity and QoL. Few patients with HF with reduced ejection fraction receive medications at target doses. Guidelines suggest rapid initiation of first-line agents from four drug classes, with a simultaneous strategy favored over a sequential one. In patients with HF with reduced ejection fraction in sinus rhythm and elevated heart rate, ivabradine should be added to maximum tolerated doses of beta-blockers. Adding ivabradine to first-line therapy improves heart rate control and QoL, and reduces HF-related hospitalization and mortality.<\/jats:p>","DOI":"10.57264\/cer-2025-0119","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:07:23Z","timestamp":1773331643000},"source":"Crossref","is-referenced-by-count":0,"title":["Personalized management of angina and heart failure in clinical practice in the Middle East: a narrative review"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6559-2631","authenticated-orcid":false,"given":"Juwairia Al","family":"Ali","sequence":"first","affiliation":[{"name":"Cardiology Department, Rashid Hospital, Dubai, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brajesh","family":"Mittal","sequence":"additional","affiliation":[{"name":"Cardiology Department, Medcare Hospital, Dubai, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fekry El","family":"Deeb","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Azhar University, Cairo, Egypt"},{"name":"Department of Cardiology &amp; Vascular System, Fakeeh University Hospital, Dubai, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Semaan","sequence":"additional","affiliation":[{"name":"Cardiology Department, Notre Dame Maritime Hospital, Byblos, Lebanon"},{"name":"Cardiology Department, Al Koura Hospital, Bsarma, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-1056","authenticated-orcid":false,"given":"Hani M","family":"Sabbour","sequence":"additional","affiliation":[{"name":"Warren Alpert Medical School, Brown University, Providence, RI, USA"},{"name":"Cardiology Department, Mediclinic Hospital Abu Dhabi, Abu Dhabi, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_10_3_2","unstructured":"World Heart Federation. Middle East & North Africa. (2024). Accessed: 28 February 2024. https:\/\/world-heart-federation.org\/where-we-work\/middle-east-north-africa\/"},{"issue":"4","key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2174\/1573406416666200611104143","article-title":"The burden of cardiovascular disease risk factors in the Middle East: a systematic review and meta-analysis focusing on primary prevention","volume":"19","author":"Bhagavathula AS","year":"2021","unstructured":"Bhagavathula AS, Shehab A, Ullah A, Rahmani J. The burden of cardiovascular disease risk factors in the Middle East: a systematic review and meta-analysis focusing on primary prevention. Curr. Vasc. Pharmacol. 19(4), 379\u2013389 (2021).","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"3","key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/HJR.0b013e328322ca1b","article-title":"Prevalence of cardiovascular risk factors in the Middle East: a systematic review","volume":"16","author":"Motlagh B","year":"2009","unstructured":"Motlagh B, O'Donnell M, Yusuf S. Prevalence of cardiovascular risk factors in the Middle East: a systematic review. Eur. J. Cardiovasc. Prev. Rehabil. 16(3), 268\u2013280 (2009).","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"issue":"25","key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth GA","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J. Am. Coll. Cardiol. 76(25), 2982\u20133021 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"e030165","DOI":"10.1161\/JAHA.123.030165","article-title":"Burden of ischemic heart disease and its attributable risk factors in North Africa and the Middle East, 1990 to 2019: results from the GBD study 2019","volume":"13","author":"Aminorroaya A","year":"2024","unstructured":"Aminorroaya A, Saeedi Moghaddam S, Tavolinejad H Burden of ischemic heart disease and its attributable risk factors in North Africa and the Middle East, 1990 to 2019: results from the GBD study 2019. J. Am. Heart Assoc. 13(2), e030165 (2024).","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37616\/2212-5043.1040","article-title":"Heart failure in the Middle East Arab countries: current and future perspectives","volume":"32","author":"Elasfar AA","year":"2020","unstructured":"Elasfar AA, Alhabeeb W, Elasfar S. Heart failure in the Middle East Arab countries: current and future perspectives. J. Saudi. Heart Assoc. 32(2), 236\u2013241 (2020).","journal-title":"J. Saudi. Heart Assoc."},{"issue":"10159","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159), 1789\u20131858 (2018).","journal-title":"Lancet"},{"issue":"10","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamainternmed.2014.3773","article-title":"Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry","volume":"174","author":"Steg PG","year":"2014","unstructured":"Steg PG, Greenlaw N, Tendera M Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA Intern. Med. 174(10), 1651\u20131659 (2014).","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/ejhf.245","article-title":"Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE)","volume":"17","author":"Sulaiman K","year":"2015","unstructured":"Sulaiman K, Panduranga P, Al-Zakwani I Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE). Eur. J. Heart Fail. 17(4), 374\u2013384 (2015).","journal-title":"Eur. J. Heart Fail."},{"issue":"7","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"e0236292","DOI":"10.1371\/journal.pone.0236292","article-title":"Acute myocardial infarction and acute heart failure in the Middle East and North Africa: study design and pilot phase study results from the PEACE MENA registry","volume":"15","author":"Alhabib KF","year":"2020","unstructured":"Alhabib KF, Gamra H, Almahmeed W Acute myocardial infarction and acute heart failure in the Middle East and North Africa: study design and pilot phase study results from the PEACE MENA registry. PLoS One 15(7), e0236292 (2020).","journal-title":"PLoS One"},{"issue":"1","key":"e_1_3_10_13_2","first-page":"A14017","article-title":"Clinical characteristics and treatment patterns in patients with heart failure: results from the iCaReMe Middle East and Africa cohort [AHA Scientific Sessions abstract 14017]","volume":"148","author":"Zarif B","year":"2023","unstructured":"Zarif B, Cavusoglu Y, Al Badarin F Clinical characteristics and treatment patterns in patients with heart failure: results from the iCaReMe Middle East and Africa cohort [AHA Scientific Sessions abstract 14017]. Circulation 148(Suppl. 1), A14017 (2023).","journal-title":"Circulation"},{"issue":"9","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11883-023-01126-x","article-title":"The pandemic of coronary heart disease in the Middle East and North Africa: what clinicians need to know","volume":"25","author":"Manla Y","year":"2023","unstructured":"Manla Y, Almahmeed W. The pandemic of coronary heart disease in the Middle East and North Africa: what clinicians need to know. Curr. Atheroscler. Rep. 25(9), 543\u2013557 (2023).","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"e_1_3_10_15_2","first-page":"2","article-title":"Expert recommendations to bridge gaps in heart failure patient support in the Middle East and Africa Region","volume":"28","author":"Skouri HN","year":"2024","unstructured":"Skouri HN, \u00c7avu\u015fo\u011flu Y, Bennis A Expert recommendations to bridge gaps in heart failure patient support in the Middle East and Africa Region. Anatol. J. Cardiol. 28(1), 2\u201318 (2024).","journal-title":"Anatol. J. Cardiol."},{"issue":"38","key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot G","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34(38), 2949\u20133003 (2013).","journal-title":"Eur. Heart J."},{"issue":"3","key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2006.01.099","article-title":"Prevalence and predictors of angina pectoris one month after myocardial infarction","volume":"98","author":"Spertus JA","year":"2006","unstructured":"Spertus JA, Dawson J, Masoudi FA Prevalence and predictors of angina pectoris one month after myocardial infarction. Am. J. Cardiol. 98(3), 282\u2013288 (2006).","journal-title":"Am. J. Cardiol."},{"issue":"20","key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","article-title":"Everolimus-eluting bioresorbable scaffolds for coronary artery disease","volume":"373","author":"Ellis SG","year":"2015","unstructured":"Ellis SG, Kereiakes DJ, Metzger DC Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N. Engl. J. Med. 373(20), 1905\u20131915 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"10157","key":"e_1_3_10_19_2","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","article-title":"Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial","volume":"392","author":"Stone GW","year":"2018","unstructured":"Stone GW, Ellis SG, Gori T Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet 392(10157), 1530\u20131540 (2018).","journal-title":"Lancet"},{"issue":"29","key":"e_1_3_10_20_2","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehy857","article-title":"Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization","volume":"40","author":"Crea F","year":"2019","unstructured":"Crea F, Bairey Merz CN, Beltrame JF Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur. Heart J. 40(29), 2455\u20132462 (2019).","journal-title":"Eur. Heart J."},{"issue":"17","key":"e_1_3_10_21_2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/eurheartj\/eht513","article-title":"Coronary microvascular dysfunction: an update","volume":"35","author":"Crea F","year":"2014","unstructured":"Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur. Heart J. 35(17), 1101\u20131111 (2014).","journal-title":"Eur. Heart J."},{"key":"e_1_3_10_22_2","first-page":"100302","article-title":"INOCA\/ANOCA: mechanisms and novel treatments","volume":"30","author":"Ashokprabhu ND","year":"2023","unstructured":"Ashokprabhu ND, Quesada O, Alvarez YR, Henry TD. INOCA\/ANOCA: mechanisms and novel treatments. Am. Heart J. Plus. 30, 100302 (2023).","journal-title":"Am. Heart J. Plus."},{"issue":"2","key":"e_1_3_10_23_2","first-page":"64","article-title":"ANOCA, INOCA, MINOCA: the new frontier of coronary syndromes","volume":"12","author":"Parlati ALM","year":"2025","unstructured":"Parlati ALM, Nardi E, Sucato V ANOCA, INOCA, MINOCA: the new frontier of coronary syndromes. J. Cardiovasc. Dev. Dis. 12(2), 64 (2025).","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"36","key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints C","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC 2024 ESC guidelines for the management of chronic coronary syndromes. Eur. Heart J. 45(36), 3415\u20133537 (2024).","journal-title":"Eur. Heart J."},{"issue":"11","key":"e_1_3_10_25_2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jacc.2012.04.046","article-title":"Rethinking stable ischemic heart disease: is this the beginning of a new era?","volume":"60","author":"Pepine CJ","year":"2012","unstructured":"Pepine CJ, Douglas PS. Rethinking stable ischemic heart disease: is this the beginning of a new era? J. Am. Coll. Cardiol. 60(11), 957\u2013959 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"37","key":"e_1_3_10_26_2","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1093\/eurheartj\/ehaa503","article-title":"An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on coronary pathophysiology & microcirculation endorsed by Coronary Vasomotor Disorders International Study Group","volume":"41","author":"Kunadian V","year":"2020","unstructured":"Kunadian V, Chieffo A, Camici PG An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on coronary pathophysiology & microcirculation endorsed by Coronary Vasomotor Disorders International Study Group. Eur. Heart J. 41(37), 3504\u20133520 (2020).","journal-title":"Eur. Heart J."},{"issue":"2","key":"e_1_3_10_27_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nrcardio.2017.131","article-title":"Expert consensus document: a \u2018diamond\u2019 approach to personalized treatment of angina","volume":"15","author":"Ferrari R","year":"2018","unstructured":"Ferrari R, Camici PG, Crea F Expert consensus document: a \u2018diamond\u2019 approach to personalized treatment of angina. Nat. Rev. Cardiol. 15(2), 120\u2013132 (2018).","journal-title":"Nat. Rev. Cardiol."},{"issue":"14","key":"e_1_3_10_28_2","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/CIRCULATIONAHA.113.004046","article-title":"The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study","volume":"129","author":"Moran AE","year":"2014","unstructured":"Moran AE, Forouzanfar MH, Roth GA The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 129(14), 1493\u20131501 (2014).","journal-title":"Circulation"},{"issue":"14","key":"e_1_3_10_29_2","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1161\/01.CIR.0000143379.26342.5C","article-title":"Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease","volume":"110","author":"Hlatky MA","year":"2004","unstructured":"Hlatky MA, Boothroyd DB, Melsop KA Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. Circulation 110(14), 1960\u20131966 (2004).","journal-title":"Circulation"},{"issue":"16","key":"e_1_3_10_30_2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archinternmed.2009.295","article-title":"The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study","volume":"169","author":"Beltrame JF","year":"2009","unstructured":"Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study. Arch. Intern. Med. 169(16), 1491\u20131499 (2009).","journal-title":"Arch. Intern. Med."},{"issue":"7","key":"e_1_3_10_31_2","first-page":"1017","article-title":"Angina and associated healthcare costs following percutaneous coronary intervention: a real-world analysis from a multi-payer database","volume":"88","author":"Ben-Yehuda O","year":"2016","unstructured":"Ben-Yehuda O, Kazi DS, Bonafede M Angina and associated healthcare costs following percutaneous coronary intervention: a real-world analysis from a multi-payer database. Catheter Cardiovasc. Interv. 88(7), 1017\u20131024 (2016).","journal-title":"Catheter Cardiovasc. Interv."},{"issue":"3","key":"e_1_3_10_32_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ehjqcco\/qcw016","article-title":"Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease","volume":"2","author":"Qintar M","year":"2016","unstructured":"Qintar M, Spertus JA, Gosch KL Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. Eur. Heart J. Qual. Care Clin. Outcomes 2(3), 208\u2013214 (2016).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"issue":"3","key":"e_1_3_10_33_2","first-page":"742","article-title":"Changes in heart rate and heart rate variability before ambulatory ischemic events","volume":"38","author":"Kop WJ","year":"2001","unstructured":"Kop WJ, Verdino RJ, Gottdiener JS, O'Leary ST, Bairey Merz CN, Krantz DS. Changes in heart rate and heart rate variability before ambulatory ischemic events. J. Am. Coll. Cardiol. 38(3), 742\u2013749 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"e_1_3_10_34_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrcardio.2011.58","article-title":"Heart rate: a forgotten link in coronary artery disease?","volume":"8","author":"Fox KM","year":"2011","unstructured":"Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat. Rev. Cardiol. 8(7), 369\u2013379 (2011).","journal-title":"Nat. Rev. Cardiol."},{"issue":"11","key":"e_1_3_10_35_2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jacc.2012.02.082","article-title":"Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link!","volume":"60","author":"Marzilli M","year":"2012","unstructured":"Marzilli M, Merz CN, Boden WE Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J. Am. Coll. Cardiol. 60(11), 951\u2013956 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"e_1_3_10_36_2","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bph.12475","article-title":"Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy","volume":"171","author":"Fillmore N","year":"2014","unstructured":"Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br. J. Pharmacol. 171(8), 2080\u20132090 (2014).","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"e_1_3_10_37_2","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehi816","article-title":"Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine\/adenosine triphosphate ratio in patients with heart failure","volume":"27","author":"Fragasso G","year":"2006","unstructured":"Fragasso G, Perseghin G, De Cobelli F Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine\/adenosine triphosphate ratio in patients with heart failure. Eur. Heart J. 27(8), 942\u2013948 (2006).","journal-title":"Eur. Heart J."},{"issue":"2","key":"e_1_3_10_38_2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.15420\/ecr.2018.15.2","article-title":"Trimetazidine and other metabolic modifiers","volume":"13","author":"Guarini G","year":"2018","unstructured":"Guarini G, Huqi A, Morrone D, Capozza PFG, Marzilli M. Trimetazidine and other metabolic modifiers. Eur. Cardiol. 13(2), 104\u2013111 (2018).","journal-title":"Eur. Cardiol."},{"issue":"4","key":"e_1_3_10_39_2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s12325-017-0490-2","article-title":"Real-world evidence for the antianginal efficacy of trimetazidine from the Russian observational CHOICE-2 study","volume":"34","author":"Glezer M","year":"2017","unstructured":"Glezer M. Real-world evidence for the antianginal efficacy of trimetazidine from the Russian observational CHOICE-2 study. Adv. Ther. 34(4), 915\u2013924 (2017).","journal-title":"Adv. Ther."},{"issue":"1","key":"e_1_3_10_40_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13054-015-0803-2","article-title":"\u03b2-blockers in critically ill patients: from physiology to clinical evidence","volume":"19","author":"Coppola S","year":"2015","unstructured":"Coppola S, Froio S, Chiumello D. \u03b2-blockers in critically ill patients: from physiology to clinical evidence. Crit. Care 19(1), 119 (2015).","journal-title":"Crit. Care"},{"issue":"4","key":"e_1_3_10_41_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00129784-200505040-00006","article-title":"Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study","volume":"5","author":"El-Kady T","year":"2005","unstructured":"El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am. J. Cardiovasc. Drugs 5(4), 271\u2013278 (2005).","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"2","key":"e_1_3_10_42_2","first-page":"57","article-title":"A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study [in Spanish]","volume":"205","author":"Rodr\u00edguez Padial L","year":"2005","unstructured":"Rodr\u00edguez Padial L, Maicas Bellido C, Vel\u00e1zquez Mart\u00edn M, Gil Polo B. A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study [in Spanish]. Rev. Clin. Esp. 205(2), 57\u201362 (2005).","journal-title":"Rev. Clin. Esp."},{"issue":"1","key":"e_1_3_10_43_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00044011-199713010-00002","article-title":"Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina","volume":"13","author":"Michaelides AP","year":"1997","unstructured":"Michaelides AP, Spiropoulos K, Dimopoulos K, Athanasiades D, Toutouzas P. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin. Drug Invest. 13(1), 8\u201314 (1997).","journal-title":"Clin. Drug Invest."},{"issue":"6","key":"e_1_3_10_44_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/clc.20888","article-title":"Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials","volume":"34","author":"Hu B","year":"2011","unstructured":"Hu B, Li W, Xu T, Chen T, Guo J. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials. Clin. Cardiol. 34(6), 395\u2013400 (2011).","journal-title":"Clin. Cardiol."},{"issue":"7","key":"e_1_3_10_45_2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s12325-018-0674-4","article-title":"The effectiveness of trimetazidine treatment in patients with stable angina pectoris of various durations: results from the CHOICE-2 study","volume":"35","author":"Glezer M","year":"2018","unstructured":"Glezer M. The effectiveness of trimetazidine treatment in patients with stable angina pectoris of various durations: results from the CHOICE-2 study. Adv. Ther. 35(7), 1103\u20131113 (2018).","journal-title":"Adv. Ther."},{"issue":"2","key":"e_1_3_10_46_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40119-020-00174-7","article-title":"Effectiveness of trimetazidine in patients with stable angina pectoris of various durations: results from ODA","volume":"9","author":"Glezer MG","year":"2020","unstructured":"Glezer MG, Vygodin VA. ODA investigators. Effectiveness of trimetazidine in patients with stable angina pectoris of various durations: results from ODA. Cardiol. Ther. 9(2), 395\u2013408 (2020).","journal-title":"Cardiol. Ther."},{"issue":"8","key":"e_1_3_10_47_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrcardio.2016.84","article-title":"Heart rate reduction in coronary artery disease and heart failure","volume":"13","author":"Ferrari R","year":"2016","unstructured":"Ferrari R, Fox K. Heart rate reduction in coronary artery disease and heart failure. Nat. Rev. Cardiol. 13(8), 493\u2013501 (2016).","journal-title":"Nat. Rev. Cardiol."},{"issue":"16","key":"e_1_3_10_48_2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","article-title":"Heart rate lowering by specific and selective I\n                  f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease","volume":"64","author":"DiFrancesco D","year":"2004","unstructured":"DiFrancesco D, Camm JA. Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64(16), 1757\u20131765 (2004).","journal-title":"Drugs"},{"issue":"1","key":"e_1_3_10_49_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.atherosclerosis.2010.11.035","article-title":"Ivabradine improves coronary flow reserve in patients with stable coronary artery disease","volume":"215","author":"Skalidis EI","year":"2011","unstructured":"Skalidis EI, Hamilos MI, Chlouverakis G, Zacharis EA, Vardas PE. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis 215(1), 160\u2013165 (2011).","journal-title":"Atherosclerosis"},{"issue":"6","key":"e_1_3_10_50_2","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.115.06091","article-title":"Impact of ivabradine on central aortic blood pressure and myocardial perfusion in patients with stable coronary artery disease","volume":"66","author":"Dillinger JG","year":"2015","unstructured":"Dillinger JG, Maher V, Vitale C Impact of ivabradine on central aortic blood pressure and myocardial perfusion in patients with stable coronary artery disease. Hypertension 66(6), 1138\u20131144 (2015).","journal-title":"Hypertension"},{"issue":"3","key":"e_1_3_10_51_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12325-018-0681-5","article-title":"Efficacy of ivabradine in combination with beta-blockers versus uptitration of beta-blockers in patients with stable angina (CONTROL-2 study)","volume":"35","author":"Glezer M","year":"2018","unstructured":"Glezer M, Vasyuk Y, Karpov Y. Efficacy of ivabradine in combination with beta-blockers versus uptitration of beta-blockers in patients with stable angina (CONTROL-2 study). Adv. Ther. 35(3), 341\u2013352 (2018).","journal-title":"Adv. Ther."},{"issue":"2","key":"e_1_3_10_52_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000219938","article-title":"Efficacy of I\n                  f inhibition with ivabradine in different subpopulations with stable angina pectoris","volume":"114","author":"Tendera M","year":"2009","unstructured":"Tendera M, Borer JS, Tardif JC. Efficacy of If inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology 114(2), 116\u2013125 (2009).","journal-title":"Cardiology"},{"issue":"5","key":"e_1_3_10_53_2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the I\n                  f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif JC","year":"2009","unstructured":"Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur. Heart J. 30(5), 540\u2013548 (2009).","journal-title":"Eur. Heart J."},{"issue":"6","key":"e_1_3_10_54_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10557-011-6327-3","article-title":"Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina","volume":"25","author":"Amosova E","year":"2011","unstructured":"Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina. Cardiovasc. Drugs Ther. 25(6), 531\u2013537 (2011).","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"19","key":"e_1_3_10_55_2","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial","volume":"30","author":"Fox K","year":"2009","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J. 30(19), 2337\u20132345 (2009).","journal-title":"Eur. Heart J."},{"issue":"3","key":"e_1_3_10_56_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000447443","article-title":"Effectiveness of ivabradine treatment in different subpopulations with stable angina in clinical practice: a pooled analysis of observational studies","volume":"135","author":"Werdan K","year":"2016","unstructured":"Werdan K, Perings S, K\u00f6ster R Effectiveness of ivabradine treatment in different subpopulations with stable angina in clinical practice: a pooled analysis of observational studies. Cardiology 135(3), 141\u2013150 (2016).","journal-title":"Cardiology"},{"issue":"3","key":"e_1_3_10_57_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.37616\/2212-5043.1320","article-title":"Saudi Heart Association guidelines on best practices in the management of chronic coronary syndromes","volume":"34","author":"AlShammeri O","year":"2022","unstructured":"AlShammeri O, Al Saif S, Al Shehri H Saudi Heart Association guidelines on best practices in the management of chronic coronary syndromes. J. Saudi. Heart Assoc. 34(3), 182\u2013211 (2022).","journal-title":"J. Saudi. Heart Assoc."},{"issue":"7","key":"e_1_3_10_58_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/2047487314533217","article-title":"Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis","volume":"22","author":"Belsey J","year":"2015","unstructured":"Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. Eur. J. Prev. Cardiol. 22(7), 837\u2013848 (2015).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"e_1_3_10_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.08.003"},{"issue":"4","key":"e_1_3_10_60_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene SJ","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J. Am. Coll. Cardiol. 72(4), 351\u2013366 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"19","key":"e_1_3_10_61_2","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene SJ","year":"2019","unstructured":"Greene SJ, Fonarow GC, DeVore AD Titration of medical therapy for heart failure with reduced ejection fraction. J. Am. Coll. Cardiol. 73(19), 2365\u20132383 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"e_1_3_10_62_2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jchf.2020.04.019","article-title":"Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations?","volume":"8","author":"Jarjour M","year":"2020","unstructured":"Jarjour M, Henri C, de Denus S Care gaps in adherence to heart failure guidelines: clinical inertia or physiological limitations? JACC Heart Fail. 8(9), 725\u2013738 (2020).","journal-title":"JACC Heart Fail."},{"issue":"1","key":"e_1_3_10_63_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/xJAHA.111.000018","article-title":"Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF","volume":"1","author":"Fonarow GC","year":"2012","unstructured":"Fonarow GC, Albert NM, Curtis AB Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF. J. Am. Heart Assoc. 1(1), 16\u201326 (2012).","journal-title":"J. Am. Heart Assoc."},{"issue":"10244","key":"e_1_3_10_64_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan M","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Jhund PS Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396(10244), 121\u2013128 (2020).","journal-title":"Lancet"},{"issue":"4","key":"e_1_3_10_65_2","doi-asserted-by":"crossref","first-page":"e008594","DOI":"10.1161\/CIRCHEARTFAILURE.121.008594","article-title":"Heart failure spending function: an investment framework for sequencing and intensification of guideline-directed medical therapies","volume":"15","author":"Allen LA","year":"2022","unstructured":"Allen LA, Teerlink JR, Gottlieb SS, Ahmad T, Lam CSP, Psotka MA. Heart failure spending function: an investment framework for sequencing and intensification of guideline-directed medical therapies. Circ. Heart Fail. 15(4), e008594 (2022).","journal-title":"Circ. Heart Fail."},{"issue":"12","key":"e_1_3_10_66_2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/CIRCULATIONAHA.120.048365","article-title":"Victims of success in failure","volume":"142","author":"Lam CSP","year":"2020","unstructured":"Lam CSP, Butler J. Victims of success in failure. Circulation 142(12), 1129\u20131131 (2020).","journal-title":"Circulation"},{"issue":"5","key":"e_1_3_10_67_2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacbts.2021.10.018","article-title":"Optimizing foundational therapies in patients with HFrEF. How do we translate these findings into clinical care?","volume":"7","author":"Sharma A","year":"2022","unstructured":"Sharma A, Verma S, Bhatt DL Optimizing foundational therapies in patients with HFrEF. How do we translate these findings into clinical care? JACC Basic Transl. Sci. 7(5), 504\u2013517 (2022).","journal-title":"JACC Basic Transl. Sci."},{"issue":"9","key":"e_1_3_10_68_2","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/ejhf.2301","article-title":"Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other","volume":"23","author":"Greene SJ","year":"2021","unstructured":"Greene SJ, Butler J, Metra M. Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other. Eur. J. Heart Fail. 23(9), 1525\u20131528 (2021).","journal-title":"Eur. J. Heart Fail."},{"issue":"9744","key":"e_1_3_10_69_2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm M","year":"2010","unstructured":"B\u00f6hm M, Swedberg K, Komajda M Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744), 886\u2013894 (2010).","journal-title":"Lancet"},{"issue":"3","key":"e_1_3_10_70_2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ejhf.1682","article-title":"Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction","volume":"22","author":"Docherty KF","year":"2020","unstructured":"Docherty KF, Shen L, Castagno D Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. Eur. J. Heart Fail. 22(3), 528\u2013538 (2020).","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"e_1_3_10_71_2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister FA","year":"2009","unstructured":"McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann. Intern. Med. 150(11), 784\u2013794 (2009).","journal-title":"Ann. Intern. Med."},{"issue":"9744","key":"e_1_3_10_72_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg K","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744), 875\u2013885 (2010).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_10_73_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study","volume":"102","author":"B\u00f6hm M","year":"2013","unstructured":"B\u00f6hm M, Borer J, Ford I Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin. Res. Cardiol. 102(1), 11\u201322 (2013).","journal-title":"Clin. Res. Cardiol."},{"issue":"7","key":"e_1_3_10_74_2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ejhf.114","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT","volume":"16","author":"Komajda M","year":"2014","unstructured":"Komajda M, B\u00f6hm M, Borer JS Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur. J. Heart Fail. 16(7), 810\u2013816 (2014).","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"e_1_3_10_75_2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ejhf.59","article-title":"The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT","volume":"16","author":"Voors AA","year":"2014","unstructured":"Voors AA, van Veldhuisen DJ, Robertson M The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. Eur. J. Heart Fail. 16(4), 426\u2013434 (2014).","journal-title":"Eur. J. Heart Fail."},{"issue":"9","key":"e_1_3_10_76_2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/ejhf.582","article-title":"Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT","volume":"18","author":"Komajda M","year":"2016","unstructured":"Komajda M, Tavazzi L, Swedberg K Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. Eur. J. Heart Fail. 18(9), 1182\u20131189 (2016).","journal-title":"Eur. J. Heart Fail."},{"issue":"22","key":"e_1_3_10_77_2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the I\n                  f inhibitor ivabradine Trial) study","volume":"59","author":"Swedberg K","year":"2012","unstructured":"Swedberg K, Komajda M, B\u00f6hm M Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study. J. Am. Coll. Cardiol. 59(22), 1938\u20131945 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"20","key":"e_1_3_10_78_2","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif JC","year":"2011","unstructured":"Tardif JC, O'Meara E, Komajda M Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur. Heart J. 32(20), 2507\u20132515 (2011).","journal-title":"Eur. Heart J."},{"key":"e_1_3_10_79_2","doi-asserted-by":"crossref","first-page":"665202","DOI":"10.3389\/fcvm.2021.665202","article-title":"In-hospital heart rate reduction with beta blockers and ivabradine early after recovery in patients with acute decompensated heart failure reduces short-term mortality and rehospitalization","volume":"8","author":"Faragli A","year":"2021","unstructured":"Faragli A, Tano GD, Carlini C In-hospital heart rate reduction with beta blockers and ivabradine early after recovery in patients with acute decompensated heart failure reduces short-term mortality and rehospitalization. Front. Cardiovasc. Med. 8, 665202 (2021).","journal-title":"Front. Cardiovasc. Med."},{"issue":"2","key":"e_1_3_10_80_2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ehf2.13182","article-title":"Combination of ivabradine and sacubitril\/valsartan in patients with heart failure and reduced ejection fraction","volume":"8","author":"Lee YH","year":"2021","unstructured":"Lee YH, Lin PL, Chiou WR Combination of ivabradine and sacubitril\/valsartan in patients with heart failure and reduced ejection fraction. ESC Heart Fail. 8(2), 1204\u20131215 (2021).","journal-title":"ESC Heart Fail."},{"issue":"27","key":"e_1_3_10_81_2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37(27), 2129\u20132200 (2016).","journal-title":"Eur. Heart J."},{"issue":"1","key":"e_1_3_10_82_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh TA","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 24(1), 4\u2013131 (2022).","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"e_1_3_10_83_2","first-page":"71","article-title":"2023 National Heart Center\/Saudi Heart Association focused update of the 2019 Saudi Heart Association guidelines for the management of heart failure","volume":"35","author":"Al Habeeb W","year":"2023","unstructured":"Al Habeeb W, Tash A, Elasfar A 2023 National Heart Center\/Saudi Heart Association focused update of the 2019 Saudi Heart Association guidelines for the management of heart failure. J. Saudi. Heart Assoc. 35(1), 71\u2013134 (2023).","journal-title":"J. Saudi. Heart Assoc."},{"issue":"17","key":"e_1_3_10_84_2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary. A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary. A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79(17), 1757\u20131780 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"e_1_3_10_85_2","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald M","year":"2021","unstructured":"McDonald M, Virani S, Chan M CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can. J. Cardiol. 37(4), 531\u2013546 (2021).","journal-title":"Can. J. Cardiol."},{"issue":"2","key":"e_1_3_10_86_2","first-page":"79","article-title":"A case-based implementation of heart failure therapies, a consensus pathway by the Saudi Heart Failure Working Group","volume":"36","author":"Bakhsh A","year":"2024","unstructured":"Bakhsh A, Jelaidan I, Chaudhary AG A case-based implementation of heart failure therapies, a consensus pathway by the Saudi Heart Failure Working Group. J. Saudi. Heart Assoc. 36(2), 79\u201390 (2024).","journal-title":"J. Saudi. Heart Assoc."},{"issue":"6","key":"e_1_3_10_87_2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano GMC","year":"2021","unstructured":"Rosano GMC, Moura B, Metra M Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 23(6), 872\u2013881 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"e_1_3_10_88_2","doi-asserted-by":"crossref","first-page":"G30","DOI":"10.1093\/eurheartj\/suv058","article-title":"Prognostic and symptomatic benefits with ivabradine: lessons from the SHIFT trial","volume":"17","author":"Komajda M","year":"2015","unstructured":"Komajda M. Prognostic and symptomatic benefits with ivabradine: lessons from the SHIFT trial. Eur. Heart J. Suppl. 17(Suppl_G), G30\u2013G36 (2015).","journal-title":"Eur. Heart J. Suppl."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:28:52Z","timestamp":1774888132000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.57264\/cer-2025-0119"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0119","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"e250119"}}